Biden-Harris: Price Cuts on 10 Drugs to Save Medicare Beneficiaries $1.5 Billion
Historic Medicare drug price negotiations to lower costs on 10 best-selling drugs, saving beneficiaries $1.5 billion in out-of-pocket costs in the program's first year.
The Biden-Harris administration announced Thursday that for the first time in history, Medicare can now negotiate drug prices, thanks to the Inflation Reduction Act, which was signed into law in 2022 by President Biden with Vice President Harris casting the tie-breaking vote.
The negotiation program could lead to an estimated $6 billion in savings on prescription drug costs for American taxpayers. People enrolled in Medicare with Medicare Part D prescription drug coverage are expected to save $1.5 billion in out-of-pocket costs beginning in 2026. The Congressional Budget Office estimated that the program will save Medicare $100 billion over the next ten years.
“It’s a relief for the millions of seniors that take these drugs to treat everything from heart failure, blood clots, diabetes, arthritis, Crohn’s disease, and more – and it’s a relief for American taxpayers,” Biden said at Biden’s and Harris’ first joint appearance since Biden announced he would not run for reelection.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
10 drugs to see price cuts of up to 79% off the 2023 list price
Since being first introduced to the market, manufacturers have steadily increased the list prices on the first 10 drugs selected for the Medicare drug price negotiation program. These drugs are among the highest total spending in Medicare Part D.
The new Medicare negotiated drug prices will cut the list prices on these drugs by between 38% and 79%, according to the Department of Health and Human Services (HHS). However, these figures don’t consider or account for the rebates and discounts that drugmakers already provide to Part D plans, information that has not been released publicly.
“I’ve been waiting for this moment for a long long time,” President Joe Biden said Thursday, during his first policy-oriented appearance with Vice President Kamala Harris since leaving the presidential race. “We pay more for prescription drugs, it’s not hyperbole, than any advanced nation in the world.”
Despite pharmaceutical companies' attempts to quash the program in federal court, the price cuts have been approved.
The 10 medications and the discounts off the 2023 list prices are as follows:
- Imbruvica: 38%
- Entresto: 53%
- Eliquis: 56%
- Xarelto: 62%
- Stelara: 66%
- Jardiance: 66%
- Enbrel: 67%
- Farxiga: 68%
- Fiasp/NovoLog: 76%
- Januvia: 79%
Seniors and people with disabilities who are on Medicare and take these drugs will also benefit from the Inflation Reduction Act’s $2,000 cap on out-of-pocket spending, which goes into effect in 2025. The cap will save 19 million beneficiaries an average of $400 per year. That's in addition to the savings from the new negotiated drug prices.
“Two years ago, as vice president, I was proud to cast the tie-breaking vote that gave Medicare the power to negotiate,” Vice President Harris said to cheering crowds. “In the two years since, we’ve been using this new power to lower the price of life-saving medication.” To illustrate, if a Medicare enrollee takes Stelara for arthritis and pays $3,459 for a 30-day supply today, they would pay only $1,174 in 2026.
And this is just the beginning. As part of Medicare’s drug price negotiation program, more drugs will be selected each year. Up to 15 additional prescription medications covered under Part D will be selected for negotiation in 2025, up to an additional 15 Part B and D drugs in 2026, and up to 20 drugs every year after that.
Among the fanfare, Steve Ubl, the president of the lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA) noted, “The administration is using the IRA’s price-setting scheme to drive political headlines, but patients will be disappointed when they find out what it means for them.”
Related Content
-
Estate Tax Quiz: Can You Pass the Test on the 40% Federal Rate?Quiz How well do you know the new 2026 IRS rules for wealth transfer and the specific tax brackets that affect your heirs? Let's find out!
-
'The 'Mamdani Effect' in New York: Can the City Afford a Millionaire Tax?State Tax Will higher income taxes drive the wealthy to flee New York in 2026?
-
The November CPI Report Is Out. Here's What It Means for Rising PricesThe November CPI report came in lighter than expected, but the delayed data give an incomplete picture of inflation, say economists.
-
The November CPI Report Is Out. Here's What It Means for Rising Prices
The November CPI report came in lighter than expected, but the delayed data give an incomplete picture of inflation, say economists.
-
I'm 73, Retired, and Dreading Winter, But I Can't Afford to Be a Snowbird. Help!How can a snowbird wannabe warm up without the expense? We asked professional wealth planners for advice.
-
5 Smart Things to Do With Your Year-End Bonus, From a Financial ProfessionalAfter you indulge your urge to splurge on a treat, consider doing adult things with the extra cash, like paying down debt, but also setting up a "fun fund."
-
Are You a Gen X Investor? Here's How You Can Protect Your Portfolio From an AI BubbleAmid talk of an AI bubble, what's the best course of action for investors in their 50s and 60s, whose retirement savings are at risk from major market declines?
-
Hey, Retirees: Put Your Charitable Gifts in a Donor-Advised Fund (and Enjoy Your Tax Break)A donor-advised fund is a simple (really!), tax-smart strategy that lets you contribute a large, tax-deductible gift now and then distribute grants over time.
-
The 7-Month Deadline That Determines Your Lifetime Medicare PremiumsUnderstanding Medicare enrollment is crucial, as missing deadlines can lead to permanent late enrollment penalties and gaps in coverage.
-
If You're a U.S. Retiree Living in Portugal, Your Tax Plan Needs a Post-NHR Strategy ASAPWhen your 10-year Non-Habitual Resident tax break ends, you could see your tax rate soar. Take steps to plan for this change well before the NHR window closes.
-
Could Target-Date Funds With Built-In Income Guarantees Be the Next Evolution in Retirement Planning?With target-date funds falling short on income certainty, retirement plans should integrate guaranteed income solutions. Here is what participants can do.
